Zantac makers GSK, Pfizer, and Sanofi also said they never manufactured or sold ranitidine and cannot face innovator liability or warning label liability claims over ranitidine bottled by other companies. Those causes of action have only been adopted in California and Massachusetts and are not valid in Connecticut, according to the companies.
“The hallmark feature of innovator liability — that it holds a brand-name company responsible for the labeling of generic products manufactured and sold by a different company — requires minimum contacts with Connecticut that plaintiffs do not and cannot allege,” the three companies argued.
Boehringer Ingelheim Pharmaceuticals Inc., Boehringer Ingelheim Corp., and Boehringer Ingelheim USA Corp. joined the other drugmakers’ motion to dismiss a sole plaintiff’s claim in the Carrano lawsuit because it was the subject of prior Delaware litigation, according to the company.
Because Boehringer maintains its U.S. headquarters in Connecticut, it did not join the other companies’ personal jurisdiction arguments.
